Zai Lab Limited - American Depositary Shares (ZLAB) closed at $26.86 on November 9, 2026, up 5.4% from the previous close, on volume of 1,910,622 shares (30-day average 1,009,589).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Thu, 5-Nov 9:00 AM ET)
Zai Lab GAAP EPS of -$0.04 beats by $0.54, revenue of $108.2M beats by $0.31M
Seeking Alpha News (Thu, 5-Nov 6:35 AM ET)
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire (Thu, 5-Nov 6:30 AM ET)
Business Wire (Fri, 23-Oct 6:33 AM ET)
Zai Lab Announces $250 Million Private Placement
Business Wire (Thu, 22-Oct 8:52 PM ET)
Business Wire (Wed, 21-Oct 7:30 AM ET)
Business Wire (Wed, 14-Oct 7:00 AM ET)
Business Wire (Tue, 29-Sep 8:07 AM ET)
Business Wire (Mon, 17-Aug 6:00 AM ET)
Market Chameleon (Mon, 20-Apr 3:52 AM ET)
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Zai Lab Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ZLAB.
As of November 9, 2026, ZLAB stock price climbed to $26.86 with 1,910,622 million shares trading.
ZLAB has a beta of 1.67, meaning it tends to be more sensitive to market movements. ZLAB has a correlation of 0.13 to the broad based SPY ETF.
ZLAB has a market cap of $3.33 billion. This is considered a Mid Cap stock.
Last quarter Zai Lab Limited - American Depositary Shares reported $108 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $284,480 and exceeded earnings estimates by $.54.
In the last 3 years, ZLAB traded as high as $44.34 and as low as $13.48.
The top ETF exchange traded funds that ZLAB belongs to (by Net Assets): IBB, CANC, SBIO, ONEQ, PGJ.
ZLAB has outperformed the market in the last year with a price return of +16.0% while the SPY ETF gained +13.4%. ZLAB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.6% and +11.8%, respectively, while the SPY returned -1.8% and -1.0%, respectively.
ZLAB support price is $24.46 and resistance is $26.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZLAB shares will trade within this expected range on the day.
